Seely Lynn's Insider Trades & SAST Disclosures
Seely Lynn's most recent trade in Lyell Immunopharma Inc was a trade of 175,000 Common Stock done at an average price of $0.6 . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Seely Lynn.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 14 Mar 2025 | 175,000 | 712,500 | - | 0.6 | 106,190 | Common Stock |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,350,000 | 1,350,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 337,500 | 537,500 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 168,750 | 168,750 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 13,254 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Seely Lynn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 200,000 | 200,000 | - | 0 | Common Stock | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 11,012 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lynn Seely | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 7,500,000 | 7,500,000 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 2,600 | 8,412 (0%) | 0% | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Lynn Seely | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 2,250 | 3,562 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Lynn Seely | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 0 | - | - | Restricted Stock Units | |
| Blueprint Medicines Corp | Lynn Seely | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 1,312 (0%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges